Keywords: AHA meeting, AstraZeneca, Crestor, Merck & Co, Cozaar, Anacetrapib, Roche, Dalcetrapib

Latest news from AHA meeting on AstraZeneca’s Crestor; Merck & Co’s Cozaar and anacetrapib; and Roche’s dalcetrapib

Article | 18 November 2009

• Print This

A new analysis of 6,801 women in the JUPITER study, presented at the American Heart Association Annual Scientific Sessions in Orlando, Florida, showed that Anglo-Swedish drug major AstraZenca’s Crestor (rosuvastatin) 20mg significantly reduced cardiovascular (CV) events (defined as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by nearly half (46%; p=0.002 versus placebo) in women without cardiovascular disease (CVD), but at increased risk of a cardiovascular event as identified by age and elevated high-sensitivity C-reactive protein (hsCRP). This analysis also showed a 42% reduction in CV events for men (p<0.001 vs placebo). >

“Nearly twice as many women die of heart attacks, strokes and other cardiovascular diseases as from all forms of cancer, including breast cancer,” said Alex Gold, executive director, clinical development, Crestor, at AstraZeneca US. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.